Kuvatris Therapeutics, Inc. (NASDAQ:PXMD) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on January 14, 2026.
The company reported Q0 revenue of $0.
Kuvatris Therapeutics, Inc.'s stock currently trades at $0.00 with a market capitalization of $0.
